Skip to content
ppharmaranks
Menu
Class IIOngoing

Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), mg total, in… recall

FDA recall D-0807-2026 · initiated Aug 6, 2026

By the pharmaranks editorial teamReviewed against the FDA (openFDA) sourcesUpdated Sep 9, 2026How we research

Baxter Healthcare Corporation recalled Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), mg… in Aug 2026 — an FDA Class II recall (D-0807-2026) because CGMP Deviations.

May cause temporary or medically reversible harm; low probability of serious harm.

Why it was recalled

CGMP Deviations

The manufacturing process itself

The FDA found the process itself out of compliance, usually before any defective product was identified.

This is a manufacturing or quality failure, not a finding that the medicine is unsafe to take — across every recall we hold, none was issued for that reason. It does not mean the batch was harmless.

Is your product affected? Check the lot number

A recall covers only specific lots. Find the lot number and expiration date on your package and compare them to the affected codes below — if yours is not listed, it was not part of this recall.

Lot # NC188692, Exp Date: 11/22/2027.

Quantity recalled: N/A

Details

Product
Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), 500 mg total, in 50 mL Single Dose Container (24 bags/carton), Rx only, Sterile Nonpyrogenic, Baxter Healthcare Corporation, Deerfield, IL 60015 USA, NDC 0338-0714-24.
Recalling company
Baxter Healthcare Corporation
Classification
Class II
Status
Ongoing
Type
Voluntary: Firm initiated
Distribution
US Nationwide; Puerto Rico; and Chile.
Initiated
Aug 6, 2026
FDA report date
Sep 9, 2026
What to do.If you have a recalled product, don't throw away questions — check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This page reproduces public FDA data and is not medical advice.

Frequently asked

Was Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), mg… recalled?
Baxter Healthcare Corporation recalled Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), mg… in Aug 2026 — an FDA Class II recall (D-0807-2026) because CGMP Deviations. May cause temporary or medically reversible harm; low probability of serious harm.
Why was Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), mg… recalled?
Per the FDA enforcement record, the reason for recall D-0807-2026 was: CGMP Deviations
Is a recalled Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), mg… dangerous to take?
An FDA recall removes specific lots from the market for a defined reason and does not by itself mean the medicine is unsafe for everyone — your specific lot may never have been affected. May cause temporary or medically reversible harm; low probability of serious harm. Check the FDA notice for the affected lot numbers and expiration dates, and ask your pharmacist or doctor before stopping a prescribed medicine. This reproduces public FDA data and is not medical advice.
Which lots of Daptomycin, in 0.9% Sodium Chloride Injection, 500 mg per 50 mL (10 mg/mL), mg… are affected?
Distributed: US Nationwide; Puerto Rico; and Chile.. The recall covers these lots — Lot # NC188692, Exp Date: 11/22/2027.. Check the lot number and expiration date on your package against this list; if yours is not listed, it was not part of recall D-0807-2026.

Source: openFDA Drug Enforcement record D-0807-2026 ↗

← All drug recalls